2026-07615Notice

Potential New Indication for Testosterone Replacement Therapy

Published Date: 4/20/2026

Notice

Summary

The FDA is exploring a new use for testosterone replacement therapy (TRT) to help men with low sex drive caused by idiopathic hypogonadism, a condition where the body doesn’t make enough testosterone for unknown reasons. Drug makers with approved TRT products have until April 30, 2026, to reach out to the FDA if they want to apply for this new treatment use. This could open doors for more men to get help and might boost TRT options on the market soon!

No Economic Impacts Identified for this Document

Your PRIA Score

Score Hidden

Personalized for You

How does this regulation affect your finances?

Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.

Free to start

Key Dates

Published Date
4/20/2026

Department and Agencies

Department
Independent Agency
Agency
Health and Human Services Department
Food and Drug Administration
Source: View HTML

Related Federal Register Documents

Previous / Next Documents

Back to Federal Register